Strides gets USFDA nod for Theophylline extended-release tablets

Strides Pharma Science Ltd announced that its subsidiary has received approval from the USFDA for its generic version of Theophylline extended-release tablets, used to manage chronic asthma and other respiratory conditions. The tablets, available in 300 mg and 450 mg doses, will be produced at their Bengaluru facility and have a market size of around USD 11.5 million.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/dDlAq1O
via IFTTT